Guizhou Xinbang Pharmaceutical Co Ltd (002390) — Financial Flexibility Index
Guizhou Xinbang Pharmaceutical Co Ltd (002390) has a Financial Flexibility Index of 0.15x as of September 2025. Free cash flow of CN¥244.63 Million (operating CF CN¥234.19 Million minus capex CN¥10.43 Million) represents 0% of total liabilities (CN¥1.62 Billion). Explore Guizhou Xinbang Pharmaceutical Co Ltd capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Guizhou Xinbang Pharmaceutical Co Ltd Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Guizhou Xinbang Pharmaceutical Co Ltd across 19 annual periods. Check 002390 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Financial Flexibility Index for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)
Year-by-year free cash flow to debt coverage for Guizhou Xinbang Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Guizhou Xinbang Pharmaceutical Co Ltd.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.38x | CN¥759.84 Million | CN¥634.97 Million | CN¥2.01 Billion | ▼ -14.1% |
| 2023 | 0.44x | CN¥926.40 Million | CN¥790.62 Million | CN¥2.10 Billion | ▲ +60.3% |
| 2022 | 0.27x | CN¥749.58 Million | CN¥590.80 Million | CN¥2.73 Billion | ▲ +8.1% |
| 2021 | 0.25x | CN¥711.74 Million | CN¥457.97 Million | CN¥2.80 Billion | ▲ +29.8% |
| 2020 | 0.20x | CN¥880.20 Million | CN¥742.11 Million | CN¥4.49 Billion | ▼ -3.8% |
| 2019 | 0.20x | CN¥1.09 Billion | CN¥886.33 Million | CN¥5.37 Billion | ▲ +2475.8% |
| 2018 | 0.01x | CN¥44.96 Million | CN¥-218.56 Million | CN¥5.69 Billion | ▼ -93.5% |
| 2017 | 0.12x | CN¥636.77 Million | CN¥201.74 Million | CN¥5.20 Billion | ▲ +126.2% |
| 2016 | 0.05x | CN¥233.65 Million | CN¥-198.59 Million | CN¥4.31 Billion | ▼ -70.7% |
| 2015 | 0.19x | CN¥709.88 Million | CN¥217.40 Million | CN¥3.84 Billion | ▲ +509.0% |
| 2014 | 0.03x | CN¥84.04 Million | CN¥-198.60 Million | CN¥2.77 Billion | ▼ -41.6% |
| 2013 | 0.05x | CN¥23.46 Million | CN¥-21.34 Million | CN¥450.69 Million | ▼ -0.4% |
| 2012 | 0.05x | CN¥16.30 Million | CN¥-36.46 Million | CN¥311.99 Million | ▼ -75.6% |
| 2011 | 0.21x | CN¥56.61 Million | CN¥-39.87 Million | CN¥264.02 Million | ▼ -53.9% |
| 2010 | 0.47x | CN¥77.12 Million | CN¥2.50 Million | CN¥165.81 Million | ▲ +109.0% |
| 2009 | 0.22x | CN¥48.40 Million | CN¥41.75 Million | CN¥217.51 Million | ▲ +64.3% |
| 2008 | 0.14x | CN¥31.83 Million | CN¥24.86 Million | CN¥235.04 Million | ▼ -52.2% |
| 2007 | 0.28x | CN¥61.44 Million | CN¥32.49 Million | CN¥216.99 Million | ▲ +42.8% |
| 2006 | 0.20x | CN¥46.61 Million | CN¥7.35 Million | CN¥235.18 Million | — |